Neoadjuvant therapy for operable breast-cancer;Tratamiento neoadyuvante del cáncer de mama operable

Medicina Clinica

Volumn 126, Issue 8, 2006, Pages 295-303

  Insa, Amelia ^a   Chirivella, Isabel ^a   Lluch, Ana ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Breast cancer; Chemotherapy; Hormonal therapy; Neoadjuvant treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; TUMOR MARKER; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 33645690905     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13085484     Document Type: Article

References (64)

1. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863-74.
2. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1995;333:1444-55.
3. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:93042.
4. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971;28:1479-99.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727-33.
6. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39:3861-5.
7. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43:1488-92.
8. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep. 1976;60:1749-60.
9. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13:424-9.
10. Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer. 1991;63:561-6.
11. Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 1994;74:1283-8.
12. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, De Maublanc MA, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990;66:119-29.
13. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822-8.
14. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539-45.
15. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer. 1992;28A:896-900.
16. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer. 1993;29A:1796-9.
17. Chollet P, Charrier S, Brain E, Cure H, Van Praagh I, Feillel V, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer. 1997;33:862-6.
18. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt). 1997;118 Suppl 8:15-8.
19. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47-52.
20. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A:645-52.
21. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995;31A:1969-75.
22. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13:547-52.
23. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179-84.
24. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-93.
25. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85.
26. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
27. Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-37.
28. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, García-Conde J, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on locoregional disease. Proc Am Soc Clin Oncol. 2002;1:34a.
29. Von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19:3506-15.
30. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-74.
31. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-66.
32. Grenn MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales M, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (CRp) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol. 2002;1:35a.
33. Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc Am Soc Clin Oncol. 2002;1:34a.
34. Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol. 1995;13:537-40.
35. Vallejo CT, Lacava JA, Pérez JE, Romero AO, Machiavelli MR, Fasce HM, et al. Prognostic factors in locally advanced breast carcinoma (LABC): randomized phase-II trial of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) vs. cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Proc Am Soc Clin Oncol. 2003;2:73.
36. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17:3412-7.
37. Pouillart P, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, et al. Final results of a phase II randomized parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (AT) as neoadjuvant treatment of local-regional breast cancer. Proc Am Soc Clin Oncol. 1999;8:73.
38. Evans TR, Yellowleeo A, Foster E, Earl H, Cameron DA, Hutcheon AW, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005;23;2988-95.
39. Von Minckwitz G, Raab G, Schuette M, Hilfrich J, Blohmer JU, Gerber B, et al. Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, NO-2,MO)-primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol. 2002;1:43a.
40. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-95.
41. a. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. MD Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4:715-34.
42. b. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150-60.
43. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-9.
44. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 2002;94:3107-14.
45. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol. 2001;19:4141-9.
46. Colleoni M, Minchella I, Mazzarol G, Noie F, Peruzzotti G, Rocca A, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol. 2000;11:1057-9.
47. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-60.
48. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9:33-41.
49. Pusztai L, Ayers M, Symmans WF, Danokosh A, Hess KR, Valero V, et al. Prospective validation of gene expression profiling-based prediction of complete pahologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol. 2003;2:1.
50. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002;8:461-8.
51. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502-9.
52. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20:17-23.
53. Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology. 1996;198: 333-40.
54. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18:3480-6.
55. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182:312-5.
56. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9:235-42.
57. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89:2187-94.
58. Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol. 2002;9:243-7.
59. Fernández A, Cortés M, Benito E, Azpeitia D, Prieto L, Moreno A, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun. 2001;22:361-6.
60. Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001;92:1080-4.
61. Julian TB, Patel N, Dusi D, Olson P, Nathan G, Jasnosz K, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2001;182:407-10.
62. Kuerer HM, Hunt K. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer patients receiving neoadjuvant chemotherapy. Semin Breast Dis. 2002;5:80-7.
63. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:188-94.
64. Kaufmann M, Von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600-8.